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See Articles, pages 1064–1072 and pages 1088–1096In hepatology, hepatocellular carcinoma (HCC), not outer space,
is the ﬁnal frontier (sorry, Star Trek fans, https://www.youtube.
com/watch?v=S6R3MiAv9ac), given its extremely heterogeneous
molecular pathogenesis, dismal prognosis and limited treatment
options [1]. Treatment of this neoplasm remains a huge unmet
need with no major successes imminent, in contrast to the recent
transformative progress in HCV antivirals, and the heightened
prospects for antiﬁbrotic therapies. Two articles, by Perra et al.
and Tarocchi et al., in this month’s Journal of Hepatology offer
valuable insights into HCC pathogenesis and treatment, respec-
tively, which represent much-needed, albeit only incremental
progress in this area.
The study by Perra et al. examines the role of Hippo signalling
pathway inactivation in experimental and human carcinogenesis.
First discovered in Drosophila, the name ‘Hippo’ refers to a pheno-
type of marked organomegaly in ﬂies associated with loss of
Hippo’s normal tumour suppressor function. In mammals, the
Hippo pathway contains a highly conserved core kinase cassette
[2–4]; when Hippo signalling is active and growth is suppressed,
two growth promoting transcriptional co-activators, YAP and Taz,
are sequestered and degraded in the cytoplasm following phos-
phorylation by the kinases MST1/2 and LATS1/2. In absence of
this phosphorylation, YAP and Taz are nuclear, where they inter-
act with the molecules TEAD1-4 to promote a range of biologic
activities, including cell fate (in part through convergence with
Wnt signalling [4]), proliferation, polarity, and, most importantly,
organ size control. In liver, the dominant contributions of YAP
activation are to organ size [5–7] and HCC [5,8,9]. In further
support of Hippo’s contribution to HCC, loss of MST1/2, which
leads to YAP activation, also causes HCC [10,11] and Hippo
dysregulation accompanies many human HCCs.
The study by Perra et al. further implicates disrupted Hippo
signalling with YAP activation in HCC pathogenesis, and speciﬁ-
cally suggests that YAP activation is an early event in carcinogen-
esis, based on two animal models and immunohistochemical
studies of human HCC. In the animal studies, the investigators
used a model originally described in 1976, in which animals areJournal of Hepatology 20
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Open access under CC BY-NC-ND license.administered a carcinogen (diethylnitrosamine, or DEN) and cell
cycle inhibitor (2-acetylaminoﬂourine), then undergo partial
hepatectomy, leading ﬁrst to massive expansion of oval cells
(i.e., rodent liver progenitor cells), then to cancer. They comple-
ment this method with another HCC model using a combination
of DEN and a methionine-choline deﬁcient diet. The authors
describe early accumulation of YAP and its target genes in
pre-neoplastic hepatocytes and in oval cells. Increased YAP was
associated with downregulation of b-TRCP, an ubiquitin ligase
molecule that ordinarily ubiquitinates YAP to hasten its degrada-
tion by the proteasome, implying that reduced ubiquitinylation
of YAP through reduced b-TRCP leads to its accumulation. A spe-
ciﬁc role for YAP in inducing carcinogenesis was supported by its
attenuation in the presence of an inhibitor of YAP signalling, ver-
teporﬁn. These ﬁndings were validated in culture using human
cell lines, and also correlated with immunohistochemical evi-
dence of YAP induction in human HCCs. They also describe YAP
accumulation in adenomas, consistent with one recent report
[12] but in contrast to another [13].
Hippo/YAP is among the ‘hottest’ intracellular pathways in
liver, and the Perra et al. paper adds to the interest in Hippo/
YAP, but also further reveals its complexity. The ﬁndings comple-
ment a lovely study by Yimlamai et al. in Cell, which implicates
YAP signalling in liver cell fate determination [14]. Altogether,
they reinforce the growing appreciation for Hippo/YAP as a regu-
lator of organ size, growth regulation, cancer, progenitor cell
ampliﬁcation and cellular identity in liver.
On the other hand, the Perra et al. study also reinforces the
dearth of adequate animal models for HCC. Moreover, given
HCC’s remarkable heterogeneity, no single model will replicate
all subtypes of HCC. The models used in this study have uncertain
relevance to human disease at best, since they do not include a
ﬁbrotic, pre-malignant phase of disease. The study would have
beneﬁted greatly from a molecular analysis of the tumours and
pre-malignant lesions to determine whether the signalling path-
ways in these models are also prominent in human disease. Given
the complexity and incomplete characterization of Hippo signal-
ling in normal and injured human liver disease, it is premature to
contemplate how to exploit new knowledge about this pathway
to develop new therapeutics. On the other hand, if YAP signalling
is consistently increased in early HCC, this could lead to its use
either as a tissue marker of early cancer, or to the discovery of
secreted molecules induced by YAP that might form the basis
for a new circulating HCC biomarker.14 vol. 61 j 969–970
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In contrast to the Perra et al. study, the article by Tarocchi
et al. has more direct translational potential. The investigators
utilize a clever approach that exploits the pathologic
re-appearance of telomerase activity in HCC, which is absent
from normal hepatocytes. Telomerase is an enzyme that restores
DNA to the ends of chromosomes, or telomeres. Not only is telo-
merase induced in HCC, but telomerase re-expression is a more
generalized feature of many human cancers [15]. Tarocchi et al.
used a pro-drug compound previously described in their studies
of pancreatic cancer [16], which is activated into the nucleoside
analogue acyclovir (ACV) by the enzymatic activity of telomerase.
Thus, only cells with active telomerase will activate the substrate
pro-drug to induce cellular apoptosis and cell cycle arrest from
acyclovir’s actions in telomerase-expressing cells. The authors
ﬁrst validate the activity of the pro-drug compound in one mur-
ine and three human hepatic cancer cell lines, then extend their
ﬁndings in vivo in an HBV transgenic mouse model that develops
tumours, as well as to a syngeneic orthotopic murine model in
which a human cell line (Hepa1-6) is directly implanted within
the liver. The culture studies demonstrate that ectopic modula-
tion of telomerase activity correlates with susceptibility to the
acyclovir pro-drug. Importantly, the strategy requires wild type
p53 activity in cells, such that Hep3B cells, which are p53 null,
were not affected, but p53 re-introduction conferred responsive-
ness. In the HBV transgenic mouse studies, three times weekly
intraperitoneal administration of the ACV pro-drug for four
weeks reduced the size of neoplastic foci, associated with
decreased a-fetoprotein levels, as well as reduced tumour cell
proliferation and increased apoptosis. Interestingly, use of the
pro-drug in combination with the clinically approved multi-
kinase inhibitor sorafenib offered no additional beneﬁt over the
pro-drug alone in this orthotopic tumour model.
The ﬁndings introduce a new mode of attack for this highly
recalcitrant tumour. The appeal of this approach is its built-in tar-
geting mechanism to selectively deliver a novel therapeutic to
tumour cells only. While promising, several hurdles remain. First,
the requirement for wild type p53 activity makes this approach
much less valuable in the 1/3 of HCCs with p53 inactivation.
Similar to p53 heterogeneity, the expression of telomerase is
not always present in HCC, and it is higher in more poorly differ-
entiated tumours, indicating that early tumours might not be as
responsive [17]. Of greater concern, some telomerase activity is
present in cirrhosis, which could lead to unwanted targeting of
acyclovir to non-malignant hepatocytes [17]. This issue reﬂects
a broader challenge in cancer, in which heterogeneity may be
present not only among tumours from different patients, but
even in a single tumour from one patient, a challenge particularly
well described in breast cancer [18]. In addition, since the ACV
pro-drug does not consistently kill tumour cells, the therapy
would need to be combined with some cytotoxic therapy, other-
wise cellular escape from the drug’s effect may emerge. Finally,
newer mouse models utilizing patient derived xenografts (PDX)
might enhance the efﬁcacy of this approach [19]. PDX models
implant human tumour tissue directly from the patient into mice
to more rapidly identify personalized combination therapies; as
yet, however, not all studies have conclusively documented
improved outcomes using these personalized avatars.
The studies highlighted in this ﬁnal Focus piece reﬂect the
remarkable arc of progress in basic and translational hepatology970 Journal of Hepatology 201over the past 30 years. As this is my last single-author Focus
article (Professor Shouval and I will share authorship of the ﬁnal
piece next month), I want to express my gratitude to Professor
Samuel and the Journal of Hepatology for this opportunity as a
Focus co-Editor. It has been a privilege to document many ﬁne
examples in the Journal of Hepatology in which investigators have
advanced our ﬁeld towards the frontiers of the future.
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